Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 79

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 79
---
 beginning of 2025, and the risk that the price of STAAR common stock could be negatively impacted if the Company failed to meet investor expectations, including if STAAR failed to meet its or analyst growth and 
 profitability objectives;                                                                                                                                                                                                                     |

| • |     | the risk that STAAR may not be able to achieve projected financial performance, including the performance 
 contemplated by the Projections;                                                                          |

| • |     | risks associated with global macroeconomic conditions, including the potential impact of such conditions on 
 demand for the Company’s cash-pay premium lenses;                                                           |

| • |     | risks associated with the Company’s high concentration of business in China, including the uncertainty                                                                                                                                            
 regarding the timing and durability of a recovery in refractive procedural volumes in China, the possibility of sustained weakness of demand in China and the related impact on the Company’s inventory in China, gross margin and profitability, 
 and the long-term potential for pricing controls in China;                                                                                                                                                                                        |

| • |     | risks associated with the Company’s standalone growth strategy of increasing sales of its lenses for lower                                                                                                                     
 diopter refractive vision correction, including for mild to moderate myopia, historical inability to meaningfully move down the diopter scale, and its strategy of increasing sales in geographies outside of China and Japan; |

| • |     | risks associated with the potential adoption or increase of tariffs, including risks relating to STAAR’s 
 expansion of its manufacturing capabilities in its Nidau, Switzerland facility;                          |

-48-

| • |     | risks associated with competition from new and existing market participants, including from lower-cost                                                                                          
 manufacturers of phakic lenses for refractive vision correction, competitors who can offer both LASIK and phakic lenses, and competitors who have greater financial and operating capabilities; |

| • |     | risks related to the Company’s research and development pipeline and roadmap, and the limited number of new 
 product introductions in the near-term; and                                                                 |

| • |     | the impact of slowing revenue growth rate on share price of STAAR’s common stock. |

| • |     | Premium over Share Trading Price. The Board considered the current and historical trading prices of STAAR                                                                                                                                         
 common stock, and the fact that the Merger Consideration of $28.00 per share in cash represented a premium of approximately 51% over the trading price of STAAR common stock at the close of trading on August 4, 2025 (the last full trading day 
 prior to announcement of the